These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 26324033)
1. Is BECLIN-1 Immunoreactivity More Effective than HBME-1 in Diagnosis of Papillary Thyroid Cancer? Yeşil C; Kandemir O; Haksever H; Dabakoğlu T Acta Chir Belg; 2015; 115(4):299-305. PubMed ID: 26324033 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM; Ibrahim TR Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837 [TBL] [Abstract][Full Text] [Related]
4. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis]. He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983 [TBL] [Abstract][Full Text] [Related]
5. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Mase T; Funahashi H; Koshikawa T; Imai T; Nara Y; Tanaka Y; Nakao A Endocr J; 2003 Apr; 50(2):173-7. PubMed ID: 12803237 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation. Atik E; Guray M; Gunesacar R; Ozgur T; Canda T Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules. Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016 [TBL] [Abstract][Full Text] [Related]
8. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses]. Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110 [TBL] [Abstract][Full Text] [Related]
9. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548 [TBL] [Abstract][Full Text] [Related]
10. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217 [TBL] [Abstract][Full Text] [Related]
12. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions. Palo S; Biligi DS Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206 [TBL] [Abstract][Full Text] [Related]
13. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1]. Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157 [TBL] [Abstract][Full Text] [Related]
14. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules. Han RL; Wang J; Zhang FJ; Zhao N; Gao BL Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909 [TBL] [Abstract][Full Text] [Related]
15. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Tan A; Etit D; Bayol U; Altinel D; Tan S Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633 [TBL] [Abstract][Full Text] [Related]
16. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291 [TBL] [Abstract][Full Text] [Related]
17. Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions. Alshenawy HA Pathol Oncol Res; 2014 Oct; 20(4):819-28. PubMed ID: 24659044 [TBL] [Abstract][Full Text] [Related]
18. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Miettinen M; Kärkkäinen P Virchows Arch; 1996 Nov; 429(4-5):213-9. PubMed ID: 8972756 [TBL] [Abstract][Full Text] [Related]
19. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility. Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma. Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]